Donate

Identifying A New Pathway Explaining Resistance to Prostate Cancer Treatment

We al are very familiar with the significant problem in the treatment of prostate cancer, even therapies that initially work stop working and our disease continues to progress. The inevitable onset of this resistance to treatment with antiandrogens (ADT) such as Lupron or Zoladex is not limited just to this class of drugs. We have [...]

Cyclophosphamide (Cytoxan®) -Another Possible 2nd Line Chemotherapy for HRPC After Docetaxil Failure

Researchers, Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. from the Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX. studied the efficacy of cyclophosphamide (CP)-based metronomic chemotherapy in men who have docetaxel-resistant hormone-refractory prostate cancer (HRPC). […]

C-Reactive Protein Confirmed As An Adverse Prognostic Marker for Men with Castration-Resistant Prostate Cancer (CRPC)

I have not had even two seconds to write about anything I saw at the AACR meeting. It will take me a few days to decompress and process my experience. In the mean time I thought I would share the following with you about inflammation and its role in survival and cancer: Researchers from the [...]

On the Horizon – Positive Efficacy Data From Phase I – II Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

Medivation, Inc. (MDVN) announced that its on-going clinical trial (phase I & II) of MDV3100 in castrate resistant prostate cancer has demonstrated both efficacy and safety in its current trials. The drug under study, MDV3100, is novel androgen receptor antagonist. This trial tracked 114 prostate cancer survivors who are hormone resistant (CRPC) for 12 weeks [...]

Go to Top